Tempus AI Inc. (TEM)

TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.

Tempus AI (NASDAQ: TEM) has already posted a strong 2x gain since its IPO, rising from $37 to $74. Although it trades at a lofty 14x trailing revenue multiple, the company's solid growth trajectory an...

Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI NASDAQ: TEM. In a world where healthcare IPOs are typically dominated by biotech com...

Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.

Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.

Tempus AI delivered strong revenue growth and beat expectations on both revenue and profit, but remains unprofitable at this stage. Sequential improvements in both revenue and loss per share highlight...

Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year inc...

The stock of Tempus AI (TEM 3.69%) gave back some of its gains after surging early in Friday's trading, but it still ended the daily session solidly in the green. The healthcare artificial intelligenc...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12...